Lumira Ventures has announced the first closing of its latest healthcare venture capital fund, Lumira Ventures V, with a target size of US$200 million. The fund is dedicated to investing in transformative biotechnology and medical technology companies across North America. Demonstrating immediate activity, the fund has already completed its first investment, contributing to a US$52 million Series B financing for a pre-commercial medical device company.
Strategic Focus and Leadership Evolution
Fund V represents a continued commitment to building globally competitive healthcare companies, including those in markets historically underserved by traditional venture capital. This initiative is the seventh investment fund established by Lumira, reinforcing its disciplined, thesis-driven investment approach. The firm will continue to provide hands-on, board-level support to its portfolio companies to drive growth and innovation.
In conjunction with the new fund, Lumira has advanced its succession plan by naming co-founder Gerry Brunk as Managing Partner. Mr. Brunk will be central to executing the fund's strategy and guiding the firm’s next phase of growth. Peter van der Velden will transition to the role of Executive Chairman, where he will continue to support strategic direction and mentor the next generation of leaders.
A Strong Track Record and Investor Confidence
Over its multi-decade history, Lumira-backed companies have achieved more than 25 successful exits and secured over 40 regulatory approvals. Innovations from these companies have impacted over 15 million patients globally and generated more than US$100 billion in cumulative revenue. Since 2024 alone, the firm has exited seven portfolio companies at a cumulative transaction value exceeding US$8 billion.
The new fund is anchored by a diversified group of returning and new institutional investors, strategic partners, and family offices. Key investors like Northleaf Capital Partners and Fonds de solidarité FTQ have voiced their continued confidence in Lumira's strategy. This sustained support reflects the firm's strong performance track record and its established cross-border platform.
Ian Carew of Northleaf Capital Partners praised Lumira's disciplined approach and deep Canadian roots as key strengths aligned with their mandate. Similarly, Maxime Pesant from Fonds de solidarité FTQ highlighted the firm's proven ability to identify and scale high-potential healthcare companies. This backing is crucial for entrepreneurs seeking to bring innovative products to the global market.
Market Opportunity and Team Growth
According to Managing Partner Gerry Brunk, the current environment presents one of the most compelling moments in decades for healthcare innovation investment. Accelerating scientific advances and pressure on health systems to adopt cost-effective solutions create significant opportunities. This landscape favors experienced specialist investors who can navigate a more selective capital market with discipline.
In a move to strengthen its team for the future, Lumira also announced the promotion of Isabelle Harris to Associate. Based in Toronto, Ms. Harris will focus on sourcing and evaluating new investment opportunities in the biotech and medtech sectors. Her promotion underscores the firm's commitment to developing a durable, next-generation investment platform and team.
The launch of Lumira Ventures V, with its US$200 million target, marks a significant milestone for the firm and the North American healthcare sector. With a refreshed leadership team, robust investor backing, and a clear strategic focus, Lumira is well-positioned to capitalize on current market trends. The fund is set to play a vital role in advancing medical innovation and supporting the growth of transformative healthcare companies.